+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients

Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients

European Urology 61(5): 1039-1047

The optimal treatment strategy for muscle-invasive bladder cancer (BCa) remains controversial. Better define the long-term outcomes of radical cystectomy (RC) alone for BCa and determine the impact of pathologic downstaging after transurethral resection in a large and homogeneous single-center series. A cohort of 1100 patients undergoing RC with pelvic lymph node dissection (PLND) without neoadjuvant therapy for urothelial carcinoma of the bladder between January 1, 1986, and December 2009 was evaluated. Patients with other than metastases to the pelvic lymph nodes were excluded. Median age was 65 yr. Clinical course, pathologic characteristics, and long-term outcomes were evaluated. Follow-up was obtained until December 2009 with a median of 38 mo and a completeness of 96.5%. RC with PLND; urinary diversion with ileal neobladder whenever possible. Primary end points were disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS) according to the tumor stage of the RC specimen versus the maximum tumor stage. The log-rank test was used to compare subgroups. The 30-d (90-d) mortality rate was 3.2% (5.2%). The 10-yr OS, DSS, and RFS rates were 44.3%, 66.8%, and 65.5%, respectively. Based on the tumor stage of the RC specimen, the 10-yr DSS rate was pT0/a/is/1 pN0: 90.5%, pT2a/b pN0: 66.8%, pT3a/b pN0: 59.7%, pT4a/b pN0: 36.6%, and pTall pN+: 16.7%. Downstaging by transurethral resection of the prostate was observed in 382 patients. Patients with maximum tumor stage pT2a/b pN0 had distinctly better 10-yr DSS rates than those with pT2a/b pN0 in the RC specimen: pT2a pN0: 92.2% versus 73.8%; pT2b: 75.0% versus 62.0%. A total of 49% female and 80% male patients received an ileal neobladder. This contemporary and homogeneous single-center series found acceptable OS, DFS, and RFS for patients undergoing RC. Pathologic downstaging had a significant impact on survival.

(PDF emailed within 0-6 h: $19.90)

Accession: 055345786

Download citation: RISBibTeXText

PMID: 22381169

DOI: 10.1016/j.eururo.2012.02.028

Related references

Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma. International Urology and Nephrology 43(4): 1067-1071, 2012

Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy. Bju International 111(3 Pt B): E37-E42, 2013

Long-term results with radical cystectomy among patients with node positive urothelial cancer of the bladder. Journal of Urology 169(4 Supplement): 382-383, 2003

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology 2018: Jco1801148, 2018

Urothelial cell carcinoma T1G2-3 Radical cystectomy or conservative therapy? Long-term results. Scandinavian Journal of Urology & Nephrology 37(Suppl 214): 50-51, 2003

Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. International Journal of Urology 22(6): 549-554, 2016

Bladder carcinoma 1: Radical cystectomy, neoadjuvant and adjuvant therapy modalities. Der Urologe. Ausg. a 37(1): 93-101, 1998

Adjuvant chemotherapy vs. observation following radical cystectomy for pT3-4 and/or pN+ urothelial carcinoma of the bladder previously treated with neoadjuvant chemotherapy. European Urology Supplements 16(3): E289-E290, 2017

Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. International Urology and Nephrology 2019, 2019

Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. Urology 111: 116-121, 2017

Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology 72(3): 613-616, 2008

Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder. Urology 77(4): 867-870, 2011

Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results. Tumori 82(5): 463-469, 1996

Bladder carcinoma: Part 1. Radical cystectomy, neoadjuvant and adjuvant therapeutic methods. Urologe Ausgabe A 37(1): 93-101, 1998

Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients. Bju International 115(5): 722-727, 2015